Subscribe To

Price Alert Latest News Economic Calendar News

MNKTQ / Mallinckrodt bankruptcy plan gains approval from federal court

Prescription opioid maker Mallinckrodt MNKTQ on Tuesday gained federal court approval to erase more than $1 billion of payments intended for people with drug addiction while handing control of the pharmaceutical company to its lenders. The U.S. Bankruptcy Court in Wilmington, Del. Read More

Demo Live Account See Partner Details

Content Topics

Mallinckrodt

Bankruptcy

Plan

Gains

Approval

From

Federal

Stock

MNKTQ

Posted: Oct 10 2023, 13:35

Author Name: Market Watch

MNKTQ News

By PRNewsWire
October 22, 2023

Mallinckrodt to Present Data on TERLIVAZ® (terlipressin) for Injection in Adult Patients with Hepatorenal Syndrome (HRS) at the American College of Gastroenterology (ACG) Annual Scientific Meeting

– Findings from two clinical studies and one health economic database analysis provide insight into HRS treatment outcomes with TERLIVAZ,1 patients'

By Market Watch
October 10, 2023

Mallinckrodt bankruptcy plan gains approval from federal court

Prescription opioid maker Mallinckrodt MNKTQ on Tuesday gained federal court approval to erase more than $1 billion of payments intended for people wi

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.